Letybo (Botulinum Toxin Type A)

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction by cleaving the SNAP‑25 protein required for vesicle fusion. This prevents nerve signals from reaching the muscle, resulting in temporary paralysis of the targeted muscle fibers and a reduction of over‑activity.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, severity of the condition, and patient characteristics. The prescriber determines the amount of units to be injected, the injection sites, and the treatment interval.

Safety data for botulinum toxin type A in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus. Women who are breastfeeding should discuss risks with their healthcare provider, as the drug may be present in small amounts in breast milk.

To request Letybo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Letybo is a botulinum toxin type A formulation comparable in mechanism to other type‑A products such as onabotulinumtoxinA and incobotulinumtoxinA. Differences may exist in unit potency, formulation excipients, and approved indications, which can influence dosing strategies and regulatory status in specific markets.

Letybo should be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Do not use the product if it has been exposed to temperatures outside this range.

Letybo is administered by a trained healthcare professional via intramuscular injection. The clinician selects appropriate injection sites, prepares the required dose, and injects the solution directly into the targeted muscle or gland using a sterile needle. The procedure is performed in a clinical setting under aseptic conditions.

Serious risks include the spread of toxin effect leading to dysphagia, respiratory muscle weakness, generalized botulism, severe allergic reactions, and vision disturbances. Patients should be monitored closely after injection, and any signs of difficulty swallowing, breathing problems, or widespread weakness should prompt immediate medical evaluation.

Letybo is contraindicated in individuals with known hypersensitivity to botulinum toxin type A or any of its excipients, and in patients with neuromuscular junction disorders such as myasthenia gravis or Lambert‑Eaton syndrome. Caution is also advised for pregnant or breastfeeding women and for patients taking medications that may potentiate neuromuscular blockade.